Abstrakt

The knowledge of the role of the digestive tract in human physiology and pathology has expanded tremendously in recent years. The human intestine is a habitat for a host complex of bacteria, fungi, viruses and Acheaea, all contributing to food digestion, fermentation, metabolism of xenobiotics as well as immune and neuroendocrine functions. Moreover, evidence is mounting that many environmental factors such as diet, drugs, stress and infection may potentially disrupt intestinal microbial milieu. Therefore, methods aimed to modulate gut microbiota are eagerly investigated and applied into daily clinical practice. Fecal microbiota transplantation (FMT) is a transplant of gut bacteria from a healthy donor to a recipent. Usually, the stool bacteria are introduced by means of colonoscopy, gastroduodenoscopy, enema, orogastric tube or orally in the form of a capsule containing freeze-dried material. The effectivness of FMT in the treatment of recurrent Clostridioides difficile infection (CDI) has been confirmed in a numer of high quality studies and is currently recommended as evidence-based therapy in clinical settings. However, FMT is promising in the treatment of other diseases, as it has proven to be an effective method of treating ulcerative colitis (UC) and is of promise in treating Crohn’s disease (CD), metabolic and neuropsychiatric disorders. Many questions related to FMT remain unanswered. A better understanding of fecal and mucosal microbial composition is needed, followed by the optimisation of regulatory issues and selection of best possible donor. Novel protocols based on a new class of probiotics as emerging alternatives to FMT in CDI are also briefly disscussed.

Przypisy

• 1. Alang N., Kelly C.R.: Weight gain after fecal microbiota transplantation. Open Forum Infect. Dis., 2015; 2: ofv004
  Google Scholar
• 2. Allen S.J., Wareham K., Wang D., Bradley C., Hutchings H., Harris W., Dhar A., Brown H., Foden A., Gravenor M.B., Mack D.: Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2013; 382(9900): 1249–57
  Google Scholar
• 3. Bakker G.J., Nieuwdorp M.: Fecal microbiota transplantation: Therapeutic potential for a multitude of diseases beyond Clostridium difficile. Microbiol. Spectr., 2017; 5: doi: 10.1128/microbiolspec.BAD-0008-2017
  Google Scholar
• 4. Balamurugan R., George G., Kabeerdoss J., Hepsiba J., Chandragunasekaran A.M., Ramakrishna B.S.: Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children. Br. J. Nutr., 2010; 103(3): 335–8
  Google Scholar
• 5. Bartnicka A., Szachta P., Gałecka M.: Faecal microbiota transplant – prospects and safety. Pomeranian J. Life Sci., 2015; 61(3): 282–6
  Google Scholar
• 6. Bennet J., Brinkman M.: Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet, 1989; 333: 164
  Google Scholar
• 7. Blaut M., Klaus S.: Intestinal microbiota and obesity. In: Appetite Control. Handbook of Experimental Pharmacology, vol. 209. Ed.: H.G. Joost. Springer, Berlin, Heidelberg 2012, 251–273
  Google Scholar
• 8. Borgia G., Maraolo A.E., Foggia M., Buonomo A.R., Gentile I.: Fecal microbiota transplantation for Clostridium difficile infection: back to the future. Expert Opin. Biol. Ther., 2015; 15(7): 1001–14
  Google Scholar
• 9. Brandt L.J., Aroniadis O.C.: An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest. Endosc., 2013; 78(2): 240–9
  Google Scholar
• 10. Burke K.E., Lamont J.T.: Fecal transplantation for recurrent Clostridium difficile infection in older adults: A review. J. Am. Geriatr. Soc., 2013; 61(8): 1394–8
  Google Scholar
• 11. Cheng Y.W., Fischer M.: The present status of fecal microbiota transplantation and its value in the elderly. Curr. Treat. Options Gastroenterol., 2017; 15(3): 349–62
  Google Scholar
• 12. Colman R.J., Rubin D.T.: Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis. J. Crohns Colitis, 2014; 8(12): 1569–81
  Google Scholar
• 13. Conroy K.P., Davidson I.M., Warnock M.: Pathogenic obesity and nutraceuticals. Proc. Nutr. Soc., 2011; 70(4): 426–38
  Google Scholar
• 14. De Angelis M., Francavilla R., Piccolo M., De Giacomo A., Gobbetti M.: Autism spectrum disorders and intestinal microbiota. Gut Microbes, 2015; 6(3): 207–13
  Google Scholar
• 15. Dudzicz S., Kujawa-Szewieczek A., Kwiecień K., Więcek A., Adamczak M.: Lactobacillus plantarum 299v reduces the incidence of Clostridium difficile infection in nephrology and transplantation ward-results of one year extended study. Nutrients, 2018; 10: E1574
  Google Scholar
• 16. Eiseman B., Silen W., Bascom G.S., Kauvar A.J.: Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery, 1958; 44(5): 854–9
  Google Scholar
• 17. Fang H., Fu L., Wang J.: Protocol for fecal microbiota transplantation in inflammatory bowel disease: A systematic review and meta-analysis. Biomed. Res. Int., 2018; 2018: 8941340
  Google Scholar
• 18. Freedberg D.E., Salmasian H., Cohen B., Abrams J.A., Larson E.L.: Receipt of antibiotics in hospitalized patients and risk for Clostridium difficile infection in subsequent patients who occupy the same bed. JAMA Intern. Med., 2016; 176(12): 1801–8
  Google Scholar
• 19. Gagliardi A., Totino V., Cacciotti F., Iebba V., Neroni B., Bonfiglio G., Trancassini M., Passariello C., Pantanella F., Schippa S.: Rebuilding the gut microbiota ecosystem. Int. J. Environ. Res. Public Health, 2018; 15(8): E1679
  Google Scholar
• 20. Goldenberg J.Z., Yap C., Lytvyn L., Lo C.K., Beardsley J., Mertz D., Johnston B.C.: Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst. Rev., 2017; 12: CD006095
  Google Scholar
• 21. Goldenberg J.Z., Mertz D., Johnston B.C.: Probiotics to prevent Clostridium difficile infection in patients receiving antibiotics. JAMA, 2018; 320(5): 499–500
  Google Scholar
• 22. Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., Calder P.C., Sanders M.E.: Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol., 2014; 11(8): 506–14
  Google Scholar
• 23. Hota S.S., Poutanen S.M.: Is a single fecal microbiota transplant a promising treatment for recurrent Clostridium difficile infection? Open Forum Infect. Dis., 2018; 5(3): ofy045
  Google Scholar
• 24. Imdad A., Nicholson M.R., Tanner-Smith E.E., Zackular J.P., Gomez-Duarte O.G., Beaulieu D.B., Acra S.: Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst. Rev., 2018; 11: CD012774
  Google Scholar
• 25. Jalanka J., Hillamaa A., Satokari R., Mattila E., Anttila V.J., Arkkila P.: The long-term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection. Aliment. Pharmacol. Ther., 2018; 47(3): 371–9
  Google Scholar
• 26. Jeon S.R., Chai J., Kim C., Lee C.H.: Current evidence for the management of inflammatory bowel diseases using fecal microbiota transplantation. Curr. Infect. Dis. Rep., 2018; 20(8): 21
  Google Scholar
• 27. Jitsumura M., Cunningham A.L., Hitchings M.D., Islam S., Davies A.P., Row P.E., Riddell A.D., Kinross J., Wilkinson T.S., Jenkins G.J., Williams J.G., Harris D.A.: Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study. BMJ Open, 2018; 8: e021987
  Google Scholar
• 28. Johnston B.C., Lytvyn L., Lo C.K., Allen S.J., Wang D., Szajewska H., Miller M., Ehrhardt S., Sampalis J., Duman D.G., Pozzoni P., Colli A., Lönnermark E., Selinger C.P., Wong S., et al.: Microbial preparations (probiotics) for the prevention of Clostridium difficile infection in adults and children: An individual patient data meta-analysis of 6,851 participants. Infect. Control. Hosp. Epidemiol., 2018; 39(7): 771–81
  Google Scholar
• 29. Juszczuk K., Grudlewska K., Mikucka A., Gospodarek E.: Fecal microbiota transplantation – methods of treatment of recurrent Clostridium difficile infections and other diseases. Postępy Hig. Med. Dośw., 2017; 71(0): 220–6
  Google Scholar
• 30. Kang D.W., Adams J.B., Gregory A.C., Borody T., Chittick L., Fasano A., Khoruts A., Geis E., Maldonado J., McDonough-Means S., Pollard E.L., Roux S., Sadowsky M.J., Lipson K.S., Sullivan M.B., et al.: Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: An open-label study. Microbiome, 2017; 5: 10
  Google Scholar
• 31. Karolewska-Bochenek K., Grzesiowski P., Banaszkiewicz A., Gawronska A., Kotowska M., Dziekiewicz M., Albrecht P., Radzikowski A., Lazowska-Przeorek I.: A two-week fecal microbiota transplantation course in pediatric patients with inflammatory bowel disease. In: Clinical Investigation. Advances in Experimental Medicine and Biology, vol. 1047. Ed.: M. Pokorski. Springer, Cham 2017, 81–7
  Google Scholar
• 32. Kunde S., Pham A., Bonczyk S., Crumb T., Duba M., Conrad H.Jr., Cloney D., Kugathasan S.: Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J. Pediatr. Gastroenterol. Nutr., 2013; 56(6): 597–601
  Google Scholar
• 33. Kushak R.I., Winter H.S., Buie T.M., Cox S.B., Phillips C.D., Ward N.L.: Analysis of the duodenal microbiome in autistic individuals: Association with carbohydrate digestion. J. Pediatr. Gastroenterol. Nutr., 2017; 64(5): e110–e116
  Google Scholar
• 34. Lahtinen S.J., Forssten S., Aakko J., Granlund L., Rautonen N., Salminen S., Viitanen M., Ouwehand A.C.: Probiotic cheese containing Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus NCFM® modifies subpopulations of fecal lactobacilli and Clostridium difficile in the elderly. Age, 2012; 34(1): 133–43
  Google Scholar
• 35. Li Q., Han Y., Dy A.B., Hagerman R.J.: The gut microbiota and autism spectrum disorders. Front. Cell. Neurosci., 2017; 11: 120
  Google Scholar
• 36. Ludwig D.S., Ebbeling C.B.: The carbohydrate-insulin model of obesity: Beyond „calories in, calories out”. JAMA Intern. Med., 2018; 178(8): 1098–1103
  Google Scholar
• 37. Lynch S.V., Pedersen O.: The human intestinal microbiome in health and disease. N. Engl. J. Med., 2016; 375(24): 2369–79
  Google Scholar
• 38. Ma Y., Liu J., Rhodes C., Nie Y., Zhang F.: Ethical issues in fecal microbiota transplantation in practice. Am. J. Bioeth., 2017; 17(5): 34–45
  Google Scholar
• 39. Maida M., Mcilroy J., Ianiro G., Cammarota G.: Faecal microbiota transplantation as emerging treatment in European countries. In: Updates on Clostridium difficile in Europe. Advances in Experimental Medicine and Biology, vol. 1050. Ed.: P. Mastrantonio, M. Rupnik. Springer, Cham 2018, 177–95
  Google Scholar
• 40. Małopolska M., Fol M.: Intestinal microbiota transplantation for the treatment of Clostridium difficile infection. Med. Dosw. Mikrobiol., 2015; 67(3–4): 207–19
  Google Scholar
• 41. Marlicz W., Wunsch E., Mydlowska M., Milkiewicz M., Serwin K., Mularczyk M., Milkiewicz P., Raszeja-Wyszomirska J.: The effect of short term treatment with probiotic VSL#3 on various clinical and biochemical parameters in patients with liver cirrhosis. J. Physiol. Pharmacol., 2016; 67(6): 867–77
  Google Scholar
• 42. Marlicz W., Yung D.E., Skonieczna-Żydecka K., Loniewski I., van Hemert S., Loniewska B., Koulaouzidis A.: From clinical uncertainties to precision medicine: the emerging role of the gut barrier and microbiome in small bowel functional diseases. Expert Rev. Gastroenterol. Hepatol., 2017; 11(10): 961–78
  Google Scholar
• 43. Martirosian G., Hryniewicz W., Ozorowski T., Pawlik K., Deptuła A.: Zakażenia Clostridioides (Clostridium) difficile: epidemiologia, diagnostyka, terapia, profilaktyka. Narodowy Instytut Leków, Warszawa 2018
  Google Scholar
• 44. McDonald L.C., Gerding D.N., Johnson S., Bakken J.S., Carroll K.C., Coffin S.E., Dubberke E.R., Garey K.W., Gould C.V., Kelly C., Loo V., Shaklee Sammons J., Sandora T.J., Wilcox M.H.: Clinical Practice Guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis., 2018; 66(7): e1–e48[45] McLure A., Clements A.C., Kirk M., Glass K.: Healthcare-associated Clostridium difficile infections are sustained by disease from the community. Bull. Math. Biol., 2017; 79(10): 2242–57[46] Michalska M., Bienias R., Wojciechowska Z.: Przeszczep mikrobiomu jelitowego jako metoda leczenia nawrotowych zakażeń Clostridium difficile. Pielęg Op. Długoter., 2017; 2017: 64–70
  Google Scholar
• 47. Moayyedi P.: Update on fecal microbiota transplantation in patients with inflammatory bowel disease. Gastroenterol. Hepatol., 2018; 14(5): 319–22
  Google Scholar
• 48. Moayyedi P., Surette M.G., Kim P.T., Libertucci J., Wolfe M., Onischi C., Armstrong D., Marshall J.K., Kassam Z., Reinisch W., Lee C.H.: Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology, 2015; 149(1): 102–9.e6
  Google Scholar
• 49. Moayyedi P., Yuan Y., Baharith H., Ford A.C.: Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials. Med. J. Aust., 2017; 207(4): 166–72[50] Narula N., Kassam Z., Yuan Y., Colombel J.F., Ponsioen C., Reinisch W., Moayyedi P.: Systematic review and meta-analysis: Fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm. Bowel Dis., 2017; 23(10): 1702–9
  Google Scholar
• 51. Paramsothy S., Paramsothy R., Rubin D.T., Kamm M.A., Kaakoush N.O., Mitchell H.M., Castaño-Rodríguez N.: Faecal microbiota transplantation for inflammatory bowel disease: A systematic review and meta-analysis. J. Crohns Colitis, 2017; 11(10): 1180–99
  Google Scholar
• 52. Plummer S., Weaver M.A., Harris J.C., Dee P., Hunter J.: Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int. Microbiol., 2004; 7(1): 59–62
  Google Scholar
• 53. Pokrzywnicka P., Gumprecht J.: Intestinal microbiota and its relationship with diabetes and obesity. Clin. Diabetol., 2016; 5: 164–72[54] Sanz Y., Santacruz A., Gauffin P.: Gut microbiota in obesity and metabolic disorders. Proc. Nutr. Soc., 2010; 69(3): 434–41
  Google Scholar
• 55. Schwan A., Sjölin S., Trottestam U., Aronsson B.: Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet, 1983; 2(8354): 845
  Google Scholar
• 56. Shen N.T., Maw A., Tmanova L.L., Pino A., Ancy K., Crawford C.V., Simon M.S., Evans A.T.: Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: A systematic review with meta-regression analysis. Gastroenterology, 2017; 152(8): 1889–1900.e9
  Google Scholar
• 57. Skonieczna-Żydecka K., Kaczmarczyk M., Łoniewski I., Lara L.F., Koulaouzidis A., Misera A., Maciejewska D., Marlicz W.: A systematic review, meta-analysis, and meta-regression evaluating the efficacy and mechanisms of action of probiotics and synbiotics in the prevention of surgical site infections and surgery-related complications. J. Clin. Med., 2018; 7(12): E556
  Google Scholar
• 58. Skonieczna-Żydecka K., Łoniewski I., Maciejewska D., Marlicz W.: Mikrobiota jelitowa i składniki pokarmowe jako determinanty funkcji układu nerwowego. Część I. Mikrobiota przewodu pokarmowego. Aktualn. Neurol., 2017; 17(4): 181–8
  Google Scholar
• 59. Skonieczna-Żydecka K., Marlicz W., Misera A., Koulaouzidis A., Łoniewski I.: Microbiome – the missing link in the gut-brain axis: Focus on its role in gastrointestinal and mental health. J. Clin. Med., 2018; 7(12): E521
  Google Scholar
• 60. Sniffen J.C., McFarland L.V., Evans C.T., Goldstein E.J.: Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS One, 2018; 13(12): e0209205
  Google Scholar
• 61. Strati F., Cavalieri D., Albanese D., De Felice C., Donati C., Hayek J., Jousson O., Leoncini S., Renzi D., Calabrò A., De Filippo C.: New evidences on the altered gut microbiota in autism spectrum disorders. Microbiome, 2017; 5(1): 24
  Google Scholar
• 62. Tariq R., Smyrk T., Pardi D.S., Tremaine W.J., Khanna S.: New-onset microscopic colitis in an ulcerative colitis patient after fecal microbiota transplantation. Am. J. Gastroenterol., 2016; 111(5): 751–2
  Google Scholar
• 63. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I.: An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 2006; 444(7122): 1027–31
  Google Scholar
• 64. van Beurden Y.H., de Groot P.F., van Nood E., Nieuwdorp M., Keller J.J., Goorhuis A.: Complications, effectiveness, and long term follow-up of fecal microbiota transfer by nasoduodenal tube for treatment of recurrent Clostridium difficile infection. United European Gastroenterol. J., 2017; 5(6): 868–79
  Google Scholar
• 65.
  Google Scholar
• 65. Vrieze A., Van Nood E., Holleman F., Salojärvi J., Kootte R.S., Bartelsman J.F., Dallinga-Thie G.M., Ackermans M.T., Serlie M.J., Oozeer R., Derrien M., Druesne A., Van Hylckama Vlieg J.E., Bloks V.W., Groen A.K., et al.: Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology, 2012; 143(4): 913–6.e7
  Google Scholar
• 66. Woodworth M.H., Carpentieri C., Sitchenko K.L., Kraft C.S.: Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review. Gut Microbes, 2017; 8(3): 225–37
  Google Scholar
• 67. Xu M.Q., Cao H.L., Wang W.Q., Wang S., Cao X.C., Yan F., Wang B.M.: Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J. Gastroenterol., 2015; 21(1): 102–11
  Google Scholar
• 68. Zhang F., Luo W., Shi Y., Fan Z., Ji G.: Should we standardize the 1,700-year-old fecal microbiota transplantation? Am. J. Gastroenterol., 2012; 107(11): 1755
  Google Scholar

Pełna treść artykułu